当前位置: 首页 >> 检索结果
共有 7372 条符合本次的查询结果, 用时 7.3010658 秒

21. Alan R Hinman.

作者: Faith McLellan.
来源: Lancet. 2026年407卷10535期1228页

22. Arghavan Salles: seeing the value of diversity, equity, and inclusion.

作者: Aarathi Prasad.
来源: Lancet. 2026年407卷10535期1224页

23. Offline: Medical culture needs reform.

作者: Richard Horton.
来源: Lancet. 2026年407卷10535期1219页

24. New hope for neurotrophin targeting in osteoarthritis pain?

作者: Tonia L Vincent.
来源: Lancet. 2026年407卷10535期1210-1211页

25. Politicisation of the US FDA: eroding integrity and trust.

作者: The Lancet.
来源: Lancet. 2026年407卷10535期1209页

26. Retraction: Cosmetic talc powder.

作者: The Editors Of The Lancet.
来源: Lancet. 2026年

27. Asbestos, talc, and The Lancet's 1977 publication - Editors' reply.

作者: The Editors Of The Lancet.
来源: Lancet. 2026年

28. Asbestos, talc, and The Lancet's 1977 publication.

作者: David Rosner.;Gerald Markowitz.
来源: Lancet. 2026年

29. Proton therapy for oropharyngeal cancer: survival, toxicity, and functional outcomes.

作者: Carlos E Vargas.
来源: Lancet. 2026年407卷10535期1213-1215页

30. Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial.

作者: David J Thomson.;James M Price.;Matthew Tyler.;Matthew Beasley.;Jim Lester.;Christopher M Nutting.;Nachi Palaniappan.;Robin Prestwich.;Shanmugasundaram Ramkumar.;Anna Thompson.;Guy Betts.;Helen Bulbeck.;Frances Charlwood.;Matthew Clarke.;Matthew Lowe.;Justin Roe.;Justine Tyler.;Lorna Wilson.;Jane L Wolstenholme.;Kevin Chiu.;Judith Christian.;Clare Cruickshank.;Deborah Gardiner.;Holly Tovey.;Catharine M West.;Emma Hall.
来源: Lancet. 2026年407卷10535期1259-1275页
The clinical benefits of intensity-modulated proton therapy (IMPT) compared with intensity-modulated radiation therapy (IMRT) for patients with oropharyngeal squamous cell carcinoma remain uncertain with respect to treatment-related effects on physical function and quality of life. We aimed to compare late functional, patient-reported, disease control, and survival outcomes between IMPT and IMRT.

31. Understanding where people with tuberculosis seek care to serve them better.

作者: Charity Oga-Omenka.;Arlene Rabvukwa.;Obioma Chijioke-Akaniro.;Nkirote Mwirigi.;Madhukar Pai.
来源: Lancet. 2026年

32. Primary sclerosing cholangitis.

作者: Erik von Seth.;Tom H Karlsen.;Atsushi Tanaka.;Cyriel Ponsioen.;Annika Bergquist.
来源: Lancet. 2026年
Primary sclerosing cholangitis is a rare, chronic cholestatic liver disease characterised by biliary inflammation and fibrosis. Inflammatory bowel disease co-occurs in 50-80% of individuals with primary sclerosing cholangitis and there is an increased risk for hepatobiliary and colorectal cancers. Primary sclerosing cholangitis presentation is highly variable but there is usually a slowly progressive fibrosis of the bile ducts with strictures, development of liver fibrosis and cirrhosis, and eventually a need for liver transplantation, after which primary sclerosing cholangitis can reoccur. Primary sclerosing cholangitis is diagnosed mostly at the asymptomatic stage but, as the disease advances, people often have itching, fatigue, upper right abdominal pain, recurrent cholangitis, or complications related to portal hypertension. There are few treatment options and its exact cause and pathogenesis remain unclear. It is widely believed that both genetic and environmental factors are important, with the intestinal microbiome increasingly recognised as crucial to disease development, progression, and outcomes. This Seminar explores the clinical features of primary sclerosing cholangitis, summarises the current understanding of its pathogenesis, and gives insights into the challenges and opportunities in managing the disease.

33. Global challenges for research on gun violence.

作者: Sandra Ley.;Lorena Barberia.;Aisha Jafri.;Adnan A Hyder.
来源: Lancet. 2026年

34. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.

作者: Jeffrey L Cummings.;Alireza Atri.;Mary Sano.;Henrik Zetterberg.;Philip Scheltens.;Filip K Knop.;Peter Johannsen.;Christian A Wichmann.;Rikke Mortensen Abschneider.;Teresa Leon.;Howard H Feldman.
来源: Lancet. 2026年
Evidence, including animal, clinical, and real-world studies in individuals with type 2 diabetes and/or obesity, suggests reduced risk of dementia and Alzheimer's disease after GLP-1 receptor agonist exposure. The evoke and evoke+ trials aimed to investigate the efficacy and safety of oral semaglutide in individuals with early Alzheimer's disease.

35. Semaglutide for Alzheimer's disease after evoke and evoke.

作者: Lon S Schneider.
来源: Lancet. 2026年

36. Learning from swine influenza, Ebola virus disease, and Legionnaires' disease in 1976.

作者: Daniel B Jernigan.;Caitlin M Rivers.
来源: Lancet. 2026年

37. Katrina Jane Allen.

作者: Andrew Green.
来源: Lancet. 2026年407卷10534期1138页

38. Survival outcome of VATS compared with open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials.

作者: Rosie A Harris.;Jacie Jiaqi Law.;Long Hao.;Dongrong Situ.;Finn Amundsen Dittberner.;Morten Bendixen.;Peter B Licht.;Chris A Rogers.;Eric Lim.
来源: Lancet. 2026年407卷10534期1182-1190页
Video-assisted thoracoscopic surgery (VATS) is currently the most common approach for pulmonary lobectomy in early-stage lung cancer. Reported advantages include less pain, fewer complications, faster recovery, and improved postoperative quality of life. The widespread adoption of VATS lobectomy is principally based on non-oncological benefits. Its oncological equivalence to open surgery remains assumed as no single trial has been powered for survival. To address this important question, we sought to conduct an individual patient data meta-analysis of eligible randomised trials.

39. Prevention of urinary stones with hydration: a randomised clinical trial of an adherence intervention.

作者: Alana C Desai.;Naim M Maalouf.;Jonathan D Harper.;Sri Sivalingam.;John C Lieske.;H Henry Lai.;Peter P Reese.;Hunter Wessells.;Hongqiu Yang.;Hussein R Al-Khalidi.;Ziya Kirkali.;Gregory E Tasian.;Charles D Scales.; .
来源: Lancet. 2026年407卷10534期1171-1181页
Increased fluid intake is universally recommended to decrease the risk of recurrent urinary stones; however, adherence is challenging. The effectiveness of interventions to maintain high fluid intake has not been well studied. We sought to determine whether a multicomponent behavioural intervention programme to promote high fluid intake reduces symptomatic stone recurrence, compared with a control.

40. Angiography-derived fractional flow reserve versus coronary angiography to guide coronary artery bypass grafting in patients undergoing surgical valve procedures with concomitant coronary artery disease in China (FAVOR IV-QVAS): a multicentre, triple-blind, randomised trial.

作者: Yunpeng Zhu.;Zhaoyun Cheng.;Yuan Zhao.;Lin Han.;Wei Zhang.;Chengxin Zhang.;Sumin Yang.;Liang Ma.;Chenhui Qiao.;Zhigang Guo.;Dan Zhu.;Xiquan Zhang.;Liangwan Chen.;Zhe Wang.;Xiaofeng Ye.;Mi Zhou.;Haiqing Li.;Jiapei Qiu.;Hong Xu.;Yanjun Sun.;Jiaxi Zhu.;Zhiyun Xu.;Guoyou Qin.;William Wijns.;Bjorn Redfors.;Sigrid Sandner.;Mario Gaudino.;Shengxian Tu.;Qiang Zhao.
来源: Lancet. 2026年407卷10534期1161-1170页
For patients undergoing surgical valve procedures with concomitant coronary artery disease, current guidelines recommend that coronary artery bypass grafting (CABG) should be anatomically guided on the basis of stenosis severity, as assessed by coronary angiography. We aimed to test whether a physiologically guided strategy using angiography-derived fractional flow reserve (FFR) could improve clinical outcomes in this population.
共有 7372 条符合本次的查询结果, 用时 7.3010658 秒